<DOC>
	<DOCNO>NCT00783744</DOCNO>
	<brief_summary>To compare efficacy combination therapy insulin glargine plus glimepiride metformin versus 2 injection insulin monotherapy premixed insulin NPH 30/70 bid term change HbA1c ( baseline endpoint ) show non-inferiority insulin glargine plus glimepiride metformin .</brief_summary>
	<brief_title>Insulin Glargine Combination Therapies Type II Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetes mellitus patient type 2 , poorly control oral antidiabetic drug treatment ( glimepiride 3 4 mg od sulfonylurea similar glimepiride 3 4 mg combination metformin dose least similar 850 mg daily ) HbA1c value ≥ 7.5 % ≤ 10.5 % FBG ≥ 120 mg/dl ( 6.6 mmol/l ) BMI ≤ 35 kg/m² The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>